weekly_roundup

BioTechSign Daily Catalyst Roundup - November 17, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, VBIO, NKTR, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 17, 2026

Daily Biotech Catalyst Digest: November 17, 2026

EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
MLTXMoonLake Immunotherapeutics82.2Aclinical activity 100%, short interest 70%, publication signal 35%
VBIOValion Bio, Inc.75.5Bdilution risk 100%, short interest 10%
NKTRNektar Therapeutics74.4Bpublication signal 100%, short interest 90%, clinical activity 75%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%
BBIOBridgeBio Pharma73.2BPDUFA timing 100%, publication signal 100%, clinical activity 100%

Recent Grade-Change Queue

  • INBX (Inhibrx Inc) currently grades C with a 55.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 83%.
  • PASG (Passage Bio) currently grades F with a 13.3/100 catalyst score. Main inputs: publication signal 65%, dilution risk 53%, short interest 10%.
  • INO (Inovio Pharmaceuticals, Inc.) currently grades D with a 40.9/100 catalyst score. Main inputs: publication signal 100%, dilution risk 89%, short interest 70%.
  • SMMT (Summit Therapeutics Inc.) currently grades C with a 54.6/100 catalyst score. Main inputs: publication signal 100%, clinical activity 92%, short interest 90%.
  • NCEL (NewcelX Ltd.) currently grades D with a 46.0/100 catalyst score. Main inputs: dilution risk 62%, short interest 10%, publication signal 5%.
  • KURA (Kura Oncology, Inc.) currently grades D with a 39.4/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 65%.
  • ARGX (argenx SE) currently grades F with a 17.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 15%, short interest 10%.
  • VBIO (Valion Bio, Inc.) currently grades B with a 75.5/100 catalyst score. Main inputs: dilution risk 100%, short interest 10%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.